Will SGK public coverage with Allianz Sigorta, Anadolu Sigorta, and Acibadem Sigorta employer plans cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Cobenfy is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by TITCK?

The TITCK named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; TITCK review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Turkish-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Turkish Medical Association (TTB) and the Ministry of Health licensing directorate verifies the active license; the TITCK application records both the prescribing physician and the dispensing facility.

Can I receive Cobenfy at home?

The dispensing facility must be Turkish-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 1,700 to 2,100 per month. Delivered quote within 24h.Get my quote

Cobenfy access in Turkey: the TITCK named-patient pathway

How patients in the Republic of Turkiye legally obtain Cobenfy (xanomeline and trospium chloride) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Turkey access Cobenfy (xanomeline and trospium chloride) for schizophrenia in adults through the TITCK named-patient pathway, a the Turkish Medicines and Medical Devices Agency (Turkiye Ilac ve Tibbi Cihaz Kurumu)-administered mechanism that allows a Turkish-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in TRY.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Cobenfy reaches patients in Turkey

Cobenfy (xanomeline plus trospium chloride, the first FDA-approved muscarinic-receptor-agonist antipsychotic, FDA-approved September 2024 for schizophrenia in adults; marketed by Bristol Myers Squibb after the Karuna Therapeutics acquisition) is not currently visible on the TITCK registered-product list at titck.gov.tr/dinamikmodul/43 as of 2026-05-31. Turkish patients access Cobenfy through the Yurt Dışından İlaç Temini named-patient programme under Additional Article 7 of Law No. 1262 and TITCK Kılavuzu Revision 14 at portal.aifd.org.tr TITCK Kılavuzu Rev. 14. The application is filed by the treating psychiatrist to the TITCK Commission for Evaluation of Medicines in Personal Treatment (Şahsi Tedavide Kullanılacak İlaçların Değerlendirilmesi Komisyonu). The Cobenfy-specific clinical justification must demonstrate insufficiency of locally-licensed options under Şahsi tedavi (personal treatment) criteria: DSM-5 schizophrenia diagnosis, prior trials of D2-blocking antipsychotics (haloperidol, risperidone, olanzapine, quetiapine, aripiprazole, paliperidone) with documented inadequate response, intolerable D2-related side effects (tardive dyskinesia, hyperprolactinaemia, metabolic syndrome), or contraindications to standard antipsychotics. The ECG and cardiovascular monitoring plan per the FDA label is documented. Clinical-approval turnaround is typically 1 to several weeks; dispensing follows through TEB or USHAŞ.

Where Cobenfy is dispensed in Turkey

Cobenfy is an oral chronic psychiatry therapy administered in psychiatry outpatient or community mental-health settings. Turkish tertiary psychiatry nodes include Bakırköy Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital in Istanbul, the country's largest specialty mental-health hospital; Erenköy Mental Health and Neurological Diseases Hospital in Istanbul; Hacettepe University Faculty of Medicine Department of Psychiatry in Ankara at hastane.hacettepe.edu.tr; Ankara University İbni Sina Hospital Department of Psychiatry; Istanbul University Cerrahpaşa Medical Faculty Hospital Department of Psychiatry; Istanbul University Çapa Faculty of Medicine Hospital Department of Psychiatry; Marmara University Pendik Training and Research Hospital Department of Psychiatry; Ege University Faculty of Medicine Department of Psychiatry in Izmir; Acıbadem Hospitals Department of Psychiatry (private tertiary); Memorial Şişli Department of Psychiatry; and Medipol Mega University Hospital Department of Psychiatry. Bakırköy Mazhar Osman is the highest-volume schizophrenia clinical centre nationally with structured tardive-dyskinesia surveillance protocols; it is the most-likely Cobenfy reference centre for treatment-resistant or D2-intolerant schizophrenia. The Turkish Psychiatric Association is the relevant professional body for prescriber accreditation and treatment-resistant schizophrenia consensus.

What Cobenfy costs in Turkey

The US reference WAC for Cobenfy is approximately USD 1,800 to USD 2,000 per 30-day supply at maintenance dose per Bristol Myers Squibb published pricing and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Annual US WAC runs USD 22,000 to USD 24,000. Under the SGK Yurt Dışından İlaç Temini framework, named-patient reimbursement is at the foreign-sourced price exempt from international reference pricing. No public TRY benchmark for Cobenfy is observed on TITCK or SGK pages as of 2026-05-31. Do not estimate. Price snapshot: 2026-05-31. The TRY/USD spot rate from the Central Bank of Türkiye on the date of any quote should be footnoted, given TRY volatility. Locally-registered atypical antipsychotics (olanzapine, risperidone, quetiapine, aripiprazole, paliperidone, clozapine) are on the SGK formulary at substantially lower per-month TRY prices; the Cobenfy SGK adjudication is conditional on documented inadequate response to or intolerance of D2-blocking options. Cost layers for SGK-insured patients: drug cost mostly absorbed by SGK; co-payments and administrative fees; the dispensing TEB or USHAŞ logistics; and Reserve Meds concierge fee where US-sourced product or expedited timing is preferred.

Funding and access barriers for Cobenfy in Turkey

Schizophrenia in Turkey is managed under the universal SGK framework; the locally-registered antipsychotic formulary is broad and reimbursement of standard atypical agents is routine. Cobenfy as a first-in-class muscarinic-agonist mechanism without a Turkish equivalent fits the Şahsi tedavi case where the patient has documented intolerance or inadequate response to D2-blocking options. SGK adjudication requires the prescribing psychiatrist to document the inadequate-response criteria or contraindications (severe tardive dyskinesia, hyperprolactinaemia not controllable with adjunctive therapy, severe metabolic syndrome, neuroleptic malignant syndrome history, intractable EPS). The clinical-committee decision is case-by-case. For SGK-insured patients, full reimbursement is generally available for approved Şahsi tedavi cases. Private health insurers (Acıbadem Sigorta, Anadolu Sigorta, AXA Sigorta, Allianz Sigorta, Mapfre Sigorta, Generali, Türk Nippon Sigorta) are supplementary; coverage of unregistered psychiatry imports is policy-specific. The dispensing channel is not the patient's local eczane but TEB at teb.org.tr or USHAŞ at ushas.com.tr; patient-facing materials must direct the reader correctly. The İTS drug-tracking-system requirement adds a track-and-trace step for any imported psychotropic medicine.

Recent regulatory and access news for Cobenfy

FDA approved Cobenfy on 26 September 2024 for schizophrenia in adults based on the EMERGENT-2 and EMERGENT-3 phase 3 trials, the first non-D2 mechanism antipsychotic approval in decades. The FDA approval letter is at accessdata.fda.gov/scripts/cder/daf. EMA marketing-authorisation review is in progress as of 2026-05-31; live status at ema.europa.eu/medicines. Bristol Myers Squibb has disclosed phase 3 development of Cobenfy in adjunctive therapy for inadequately controlled schizophrenia and in Alzheimer's disease psychosis with results read-outs expected through 2026 to 2027. TITCK published Revision 14 of the Yurt Dışından İlaç Temini ve Kullanımı Kılavuzu on 29 August 2024; the İTS regulation per Anadolu Ajansı applies to any Cobenfy import.

Where Reserve Meds fits in Cobenfy cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace TITCK, and we do not replace your dispensing pharmacy. For Cobenfy specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Turkey, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Cobenfy case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the TITCK application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Turkish specialty care concentrates at the Acibadem, American Hospital, and Memorial chains in Istanbul, with Hacettepe University Hospital in Ankara serving as the principal academic referral centre; the TITCK named-patient supply pathway is routed through the Turkish Pharmacists Association (TEB) foreign medicines channel.

Next step

If your Turkish physician has prescribed Cobenfy and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Cobenfy case Or message us on WhatsApp